Codexis (CDXS) Posts Earnings Results, Beats Estimates By $0.03 EPS

Codexis (NASDAQ:CDXS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03, Morningstar.com reports. Codexis had a negative net margin of 29.83% and a negative return on equity of 61.93%. The company had revenue of $16.95 million for the quarter, compared to analyst estimates of $14.63 million. Codexis updated its FY 2018 guidance to EPS.

Shares of CDXS traded down $1.01 during trading hours on Friday, reaching $15.71. 341,487 shares of the stock traded hands, compared to its average volume of 301,554. Codexis has a 52 week low of $5.70 and a 52 week high of $19.60.

In other Codexis news, Director Patrick Y. Yang sold 150,340 shares of Codexis stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $14.45, for a total value of $2,172,413.00. Following the sale, the director now owns 120,896 shares of the company’s stock, valued at $1,746,947.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Gordon Sangster sold 80,000 shares of Codexis stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $16.94, for a total transaction of $1,355,200.00. Following the completion of the sale, the chief financial officer now directly owns 174,453 shares in the company, valued at approximately $2,955,233.82. The disclosure for this sale can be found here. Insiders have sold 508,329 shares of company stock worth $8,354,797 over the last three months. 11.40% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its position in Codexis by 29.1% in the second quarter. Rhumbline Advisers now owns 48,661 shares of the biotechnology company’s stock worth $701,000 after acquiring an additional 10,983 shares during the period. Bank of New York Mellon Corp raised its position in Codexis by 17.3% in the second quarter. Bank of New York Mellon Corp now owns 204,032 shares of the biotechnology company’s stock worth $2,939,000 after acquiring an additional 30,124 shares during the period. Baillie Gifford & Co. raised its position in Codexis by 14.9% in the second quarter. Baillie Gifford & Co. now owns 2,646,240 shares of the biotechnology company’s stock worth $38,107,000 after acquiring an additional 343,261 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Codexis by 25.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,210 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 3,475 shares during the period. Finally, Castleark Management LLC purchased a new position in shares of Codexis in the second quarter worth about $6,239,000. 77.40% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on CDXS. BidaskClub lowered shares of Codexis from a “buy” rating to a “hold” rating in a research report on Saturday, October 13th. Craig Hallum raised their price target on shares of Codexis from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th. Finally, Zacks Investment Research lowered shares of Codexis from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 15th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.40.

TRADEMARK VIOLATION NOTICE: “Codexis (CDXS) Posts Earnings Results, Beats Estimates By $0.03 EPS” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/11/10/codexis-cdxs-posts-earnings-results-beats-estimates-by-0-03-eps.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Story: What is Cost of Debt?

Earnings History for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply